Hydromorphon Al (Hydromorphone Hydrochloride)

Hydromorphone binds to µ‑opioid receptors in the brain and spinal cord, inhibiting the release of pain‑transmitting neurotransmitters. This reduces neuronal excitability and alters pain perception, providing analgesia while also producing sedation and, at high doses, respiratory depression.

The exact dose of Hydromorphon Al is individualized by the prescribing clinician based on the patient’s pain intensity, prior opioid exposure, age, organ function and other clinical factors. No fixed regimen can be provided without a medical assessment.

Safety data for hydromorphone in pregnancy and lactation are limited. Because opioids can cause neonatal respiratory depression and may affect fetal development, the drug is generally avoided unless the potential benefit justifies the risk. Consultation with a specialist is essential.

To request Hydromorphon Al, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Hydromorphone is roughly five to seven times more potent than morphine on a milligram‑for‑milligram basis, allowing lower doses for comparable analgesia. Both act on µ‑opioid receptors, but hydromorphone has a shorter half‑life and may produce less histamine‑related itching than morphine.

Hydromorphon Al should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and heat sources to maintain potency and stability.

Hydromorphon Al is supplied as an oral tablet intended for swallowing whole with a full glass of water. It should be taken exactly as prescribed, and crushing or chewing the tablet is not recommended unless directed by a healthcare professional.

The most critical risks include respiratory depression, especially after dose escalation or in patients with compromised breathing; severe hypotension; and the potential for physical dependence, tolerance and addiction. Prompt medical attention is required if breathing becomes shallow or irregular.

Hydromorphon Al is contraindicated in patients with known hypersensitivity to hydromorphone or any component of the formulation, in those with severe respiratory depression, acute asthma attacks, or paralytic ileus. Caution is also advised for individuals with uncontrolled head injury or severe hepatic impairment.